共 50 条
- [21] Tapinarof cream for the treatment of atopic dermatitis: Efficacy and safety results from two Japanese phase 3 trialsJOURNAL OF DERMATOLOGY, 2024, 51 (11): : 1404 - 1413Igarashi, AtsuyukiTsuji, GakuFukasawa, ShuichiMurata, RyuseiYamane, Satoshi
- [22] Tapinarof cream 1% once daily: Significant efficacy in the treatment of moderate to severe atopic dermatitis in adults and children down to 2 years of age in the pivotal phase 3 ADORING trialsJOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2024, 91 (03) : 457 - 465Silverberg, Jonathan I.Eichenfield, Lawrence F.Hebert, Adelaide A.Simpson, Eric L.Gold, Linda SteinBissonnette, RobertPapp, Kim A.Browning, JohnKwong, PearlKorman, Neil J.Brown, Philip M.Rubenstein, David S.Piscitelli, Stephen C.Somerville, Matthew C.Tallman, Anna M.Kircik, Leon
- [23] Patient-reported outcomes of ruxolitinib cream for the treatment of atopic dermatitis: Pooled results from two phase 3 studiesJOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB178 - AB178Simpson, Eric L.Augustin, MatthiasThaci, DiamantMisery, LaurentSilverberg, Jonathan I.Armstrong, April W.Fuxench, Zelma C. ChiesaKuligowski, Michael E.Venturanza, May E.Sun, KangPapp, Kim
- [24] Crisaborole ointment improves global atopic dermatitis severity: Pooled results from two phase 3 clinical trialsAUSTRALASIAN JOURNAL OF DERMATOLOGY, 2018, 59 : 66 - 66Fowler, J. F.Sidbury, B.Zaenglein, A. L.Pariser, D. M.Cook-Bolden, F. E.
- [25] Crisaborole ointment improves global atopic dermatitis severity: Pooled results from two phase 3 clinical trialsJOURNAL OF INVESTIGATIVE DERMATOLOGY, 2017, 137 (10) : S193 - S193Fowler, J.Sidbury, R.Zaenglein, A. L.Pariser, D. M.Cook-Bolden, F. E.
- [26] Crisaborole ointment improves global atopic dermatitis severity: Pooled results from two phase 3 clinical trialsJOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (06) : AB86 - AB86Fowler, JosephSidbury, RobertZaenglein, AndreaPariser, DavidCook-Bolden, Fran
- [27] Effects of ruxolitinib cream on work productivity and activity impairment in patients with atopic dermatitis: Pooled results from two phase 3 studiesJOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB179 - AB179Eichenfield, Lawrence F.Silverberg, Jonathan I.Kuligowski, Michael E.Venturanza, May E.Sun, KangAugustin, Matthias
- [28] Long-term safety and disease control with Ruxolitinib cream in atopic dermatitis: Pooled results from two phase 3 studiesEXPERIMENTAL DERMATOLOGY, 2021, 30 : 43 - 43Papp, K.Szepietowski, J. C.Kircik, L.Toth, D.Eichenfield, L. F.Forman, S. B.Kuligowski, M. E.Venturanza, M. E.Ren, H.Simpson, E. L.
- [29] Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double- blind, randomised controlled phase 3 trialsLANCET, 2021, 397 (10290): : 2151 - 2168Guttman-Yassky, EmmaTeixeira, Henrique D.Simpson, Eric L.Papp, Kim A.Pangan, Aileen L.Blauvelt, AndrewThaci, DiamantChu, Chia-YuHong, H. Chih-HoKatoh, NoritoPaller, Amy S.Calimlim, BrianGu, YihuaHu, XiaofeiLiu, MengYang, YangLiu, JohnTenorio, Allan R.Chu, Alvina D.Irvine, Alan D.
- [30] Rapid and early onset of itch relief with tapinarof cream 1% once daily in two pivotal phase 3 trials in adults and children down to two years of age with atopic dermatitisBRITISH JOURNAL OF DERMATOLOGY, 2024, 190 : II18 - II19Simpson, EricSilverberg, Jonathan, IBissonnette, RobertGold, Linda SteinArmstrong, AprilHebert, Adelaide A.Serrao, Rocco T.Jakus, Jeannette R.Brown, Philip M.Rubenstein, David S.Piscitelli, Stephen C.Tallman, Anna M.Eichenfield, Lawrence F.